The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006
Open accessAbstract
BACKGROUND.: The treatment of metastatic renal cell carcinoma (RCC) with high‐dose interleukin‐2 (HD IL‐2) has resulted in durable tumor regression in a minority of patients. The current study presents the authors' 20‐year experience administering this immunotherapeutic agent. METHODS.: Patients with metastatic RCC (n = 259) were treated with HD IL‐2 alone from January 13, 1986 through December 31, 2006 at the Surgery Branch of the National Cancer Institute. Potential predictive factors for response and survival, both pretreatment and treatment‐related, were first subjected to univariate analysis and then to multivariate logistic regression or a Cox proportional hazards model. Finally, the authors investigated Memorial Sloan‐Kettering Cancer Center (MSKCC) prognostic factors for survival to assess their predictive value in the patient population in the current study. RESULTS.: A total of 23 patients experienced a complete response and 30 patients achieved a partial response, for an overall objective response rate of 20%. All partial responders had developed disease recurrence at the time of last follow‒up, but only 4 complete responders had experienced disease recurrence by that time. Despite toxicities, only 2 patients developed treatment‐related mortalities over this same time period. A higher baseline weight (P = .05) and MSKCC prognostic factors (P = .02) were found to be the variables most associated with response. For survival >4 years and overall survival, several pretreatment and treatment‒related factors maintained significance, but none more so than response (P < .0001). CONCLUSIONS.: HD IL‐2 can induce complete tumor regression in a small number of patients, and many patients have experienced extended disease‐free intervals. Given its relative safety, HD IL‐2 should still be considered a first‐line therapy in patients with metastatic RCC who have an overall good performance status. Cancer 2008. Published 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Fleiss, J. L., & Agresti, A. (1991) · Journal of the American Statistical Association · doi:10.2307/2290537 · Cited by 2,641
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Self-citationExperience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Self-citationA Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables
Mehta, C. R., & Patel, N. R. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10477989 · Cited by 898
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Self-citationBUI, M. H. T., Seligson, D. B., Han, K. R., Pantuck, A. J., Dorey, F. J., Huang, Y., Horvath, S., Leibovich, B. C., Chopra, S., Liao, S. Y., et al. (2003) · PubMed · Cited by 654
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
Self-citationA Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables
Mehta, C. R., & Patel, N. R. (1983) · Journal of the American Statistical Association · doi:10.2307/2288652 · Cited by 538
Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 485
Self-citationCarbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Atkins, M. B., Regan, M. M., McDermott, D. F., Mier, J. W., Stanbridge, E. J., Youmans, A. J., Febbo, P. G., Upton, M. P., Lechpammer, M., & Signoretti, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2019 · Cited by 402
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S., & White, D. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1863 · Cited by 374
Self-citationSleijfer, D. T., Janssen, R. A., Buter, J., de Vries, E. G., Willemse, P. H., & Mulder, N. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1119 · Cited by 169
Rosenberg, S. A., Yang, J., White, D. E., & Steinberg, S. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68669-7 · Cited by 116
Self-citationBock, S. N., Lee, R. E., Fisher, B., Rubin, J. T., Schwartzentruber, D. J., Wei, J. P., Callender, D. P., Yang, J. C., Lotze, M. T., & Pizzo, P. A. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.161 · Cited by 101
Self-citationYang, J. C.-H., Topalian, S. L., Schwartzentruber, D. J., Parkinson, D. R., Marincola, F. M., Weber, J. S., Seipp, C. A., White, D. E., & Rosenberg, S. A. (1995) · Cancer · Cited by 94
Self-citationCorrelates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
Royal, R. E., Steinberg, S. M., Krouse, R. S., Heywood, G., White, D. E., Hwu, P., Marincola, F. M., Parkinson, D. R., Schwartzentruber, D. J., Topalian, S. L., et al. (1996) · PubMed · Cited by 70
Self-citation
Cited by
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Self-citationSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Self-citationVaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Metadata
- Authors
- Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-07-08
- Volume
- 113
- Issue
- 2
- Pages
- 293-301
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1992350807
- Cited by
- 434
- References
- 24
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.